jocelyn-mays
Uploaded by
45 SLIDES
587 VUES
450LIKES

Evaluating MDS HSCT Outcomes: Survival, Patient Characteristics, and Treatment Implications

DESCRIPTION

This report details the evaluation of myelodysplastic syndromes (MDS) in transplant settings, focusing on hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) and MDS across different age groups. It assesses transplant-related mortality (TRM), relapse rates, and overall survival metrics, related to various conditioning regimens and the pharmacokinetics of busulfan. The impact of azacitidine therapy and a new cytogenetic scoring system on patient outcomes is explored, alongside the implications of comorbidity indices on life expectancy in treated populations.

1 / 45

Télécharger la présentation

Evaluating MDS HSCT Outcomes: Survival, Patient Characteristics, and Treatment Implications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Activity Goals

  2. Case 1: MDS

  3. Evaluation for Transplant

  4. CCI Impacts Survival

  5. Patient Characteristics -- MDS

  6. HSCT for AML and MDS By Age: TRM and Relapse

  7. Overall Survival: HSCT for MDS By Age

  8. Conditioning Regimens

  9. Pharmacokinetics: Goal of Therapy

  10. Implications of Altered Drug Distribution of Bu

  11. Improving Outcomes

  12. Response to Azacitidine: IWG Criteria ITT Cohort (n = 282)

  13. New Cytogenetic Scoring System in MDS

  14. Survival by 5-group Cytogenetic Classification

  15. Azacitidine After Allo-SCT

  16. 3-Year OS Based On Pretransplantation Treatment

  17. Case 2: Myeloma Transformed into AML

  18. Life Expectancy at Age 65 Years and 85 Years by Gender

  19. Impact of Charlson Comorbidity Index

  20. 2-year NRM Stratified by HCTCI Scores

  21. Chronic GVHD

  22. Functional Assessment

  23. Case 2 (cont)

  24. Case 3: CML

  25. Case 3: CML (cont)

  26. Multivariate Analysis: DFS

  27. Conditioning Regimens

  28. Mutation-Dependent Maintenance Therapy

  29. Abbreviations

  30. Abbreviations (cont)

  31. Abbreviations (cont)

  32. Abbreviations (cont)

  33. References

  34. References (cont)

  35. References (cont)

  36. References (cont)

  37. References (cont)

  38. References (cont)

  39. References (cont)

  40. References (cont)

  41. References (cont)

  42. References (cont)

  43. References (cont)

  44. References (cont)

More Related